Suven Pharma’s total revenues grew 40% YoY to Rs.364 crore with the Formulations and CRAMS (pharma) reporting stellar growth this quarter on a YoY basis. Specialty chemicals reported growth of 24% in Q4FY22 (YoY) while registering a 51% growth in FY22. As result, EBITDA grew by 68% YoY despite elevated employee cost and raw material expenses.
